Pulmonary Arterial Hypertension (PAH) is a rare, progressive, and life-threatening form of high blood pressure that affects the arteries in the lungs and the right side of the heart. It is a type of cardiovascular disease, and is treated with a variety of drugs. These drugs are used to reduce symptoms, improve exercise capacity, and slow the progression of the disease. Commonly used drugs include prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and soluble guanylate cyclase stimulators. The PAH drug market is a rapidly growing segment of the cardiovascular drug market. It is driven by the increasing prevalence of PAH, the development of new drugs, and the increasing awareness of the disease. The market is expected to continue to grow in the coming years, as new drugs are developed and approved. Some of the major companies in the PAH drug market include Actelion Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, and United Therapeutics. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
